MedTrace Logo

Imaging of in Vivo Sigma-2 Receptor Expression With 18F-ISO-1 Positron Emission Tomography in Metastatic Breast Cancer

NCT03057743 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 4

Last updated 2021-11-18

No results posted yet for this study

Summary

Pilot study using \[18F\]ISO-1 PET/CT to image sigma-2 receptor binding in metastatic breast cancer. Correlate baseline uptake and change in uptake after therapy with time to progression and standard and experimental pathology assays of biopsy or surgical tissue. The target population is up to 30 adult patients at least 18 years, with at least one site of disease outside the liver by at least one type of standard imaging.

Conditions

Interventions

DEVICE

Positron emission tomography (PET/CT) imaging

DEVICE

radiotracer [18F]ISO-1

Sponsors & Collaborators

  • Abramson Cancer Center at Penn Medicine

    lead OTHER

Principal Investigators

  • Elizabeth MdDonald, MD, Ph.D · Abramson Cancer Center at Penn Medicine

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-05
Primary Completion
2021-11-01
Completion
2021-11-01
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03057743 on ClinicalTrials.gov